CTX 340
Alternative Names: CTX-340Latest Information Update: 23 May 2024
At a glance
- Originator CRISPR Therapeutics
- Class Antihypertensives; Gene therapies
- Mechanism of Action Angiotensinogen expression inhibitors; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hypertension